6 results on '"Einsele, Herrmann"'
Search Results
2. [ 68 Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [ 18 F]FDG and laboratory values.
- Author
-
Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester HJ, Knop S, and Lückerath K
- Subjects
- Adult, Aged, Aged, 80 and over, Clinical Laboratory Techniques, Female, Humans, Male, Middle Aged, Coordination Complexes administration & dosage, Fluorodeoxyglucose F18 administration & dosage, Multiple Myeloma diagnosis, Multiple Myeloma pathology, Peptides, Cyclic administration & dosage, Positron Emission Tomography Computed Tomography methods, Receptors, CXCR4 analysis
- Abstract
Chemokine (C-X-C motif) receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer including multiple myeloma (MM). Proof-of-concept of CXCR4-directed radionuclide therapy in MM has recently been reported. This study assessed the diagnostic performance of the CXCR4-directed radiotracer [
68 Ga]Pentixafor in MM and a potential role for stratifying patients to CXCR4-directed therapies. Thirty-five patients with MM underwent [68 Ga]Pentixafor-PET/CT for evaluation of eligibility for endoradiotherapy. In 19/35 cases, [18 F]FDG-PET/CT for correlation was available. Scans were compared on a patient and on a lesion basis. Tracer uptake was correlated with standard clinical parameters of disease activity. [68 Ga]Pentixafor-PET detected CXCR4-positive disease in 23/35 subjects (66%). CXCR4-positivity at PET was independent from myeloma subtypes, cytogenetics or any serological parameters and turned out as a negative prognostic factor. In the 19 patients in whom a comparison to [18 F]FDG was available, [68 Ga]Pentixafor-PET detected more lesions in 4/19 (21%) subjects, [18 F]FDG proved superior in 7/19 (37%). In the remaining 8/19 (42%) patients, both tracers detected an equal number of lesions. [18 F]FDG-PET positivity correlated with [68 Ga]Pentixafor-PET positivity (p=0.018). [68 Ga]Pentixafor-PET provides further evidence that CXCR4 expression frequently occurs in advanced multiple myeloma, representing a negative prognostic factor and a potential target for myeloma specific treatment. However, selecting patients for CXCR4 directed therapies and prognostic stratification seem to be more relevant clinical applications for this novel imaging modality, rather than diagnostic imaging of myeloma., Competing Interests: HJW is founder and shareholder of Scintomics. SK is CEO of Scintomics. All other authors declare no conflicts of interest.- Published
- 2017
- Full Text
- View/download PDF
3. 11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.
- Author
-
Lückerath K, Lapa C, Albert C, Herrmann K, Jörg G, Samnick S, Einsele H, Knop S, and Buck AK
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Positron-Emission Tomography methods, Survival Analysis, Methionine analysis, Multiple Myeloma diagnostic imaging, Radiopharmaceuticals analysis
- Abstract
Multiple myeloma (MM) remains an essentially incurable hematologic malignancy. However, new treatment modalities and novel drugs have been introduced and thus additional tools for therapy monitoring are increasingly needed. Therefore, we evaluated the radiotracers 11C-Methionine (paraprotein-biosynthesis) and 18F-FDG (glucose-utilization) for monitoring response to anti-myeloma-therapy and outcome prediction. Influence of proteasome-inhibition on radiotracer-uptake of different MM cell-lines and patient-derived CD138+ plasma cells was analyzed and related to tumor-biology. Mice xenotransplanted with MM.1S tumors underwent MET- and FDG-μPET. Tumor-to-background ratios before and after 24 h, 8 and 15 days treatment with bortezomib were correlated to survival. Treatment reduced both MET and FDG uptake; changes in tracer-retention correlated with a switch from high to low CD138-expression. In xenotransplanted mice, MET-uptake significantly decreased by 30-79% as early as 24 h after bortezomib injection. No significant differences were detected thus early with FDG. This finding was confirmed in patient-derived MM cells. Importantly, early reduction of MET- but not FDG-uptake correlated with improved survival and reduced tumor burden in mice. Our results suggest that MET is superior to FDG in very early assessment of response to anti-myeloma-therapy. Early changes in MET-uptake have predictive potential regarding response and survival. MET-PET holds promise to individualize therapies in MM in future.
- Published
- 2015
- Full Text
- View/download PDF
4. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation.
- Author
-
Lapa C, Lückerath K, Malzahn U, Samnick S, Einsele H, Buck AK, Herrmann K, and Knop S
- Subjects
- Adult, Aged, Female, Fluorodeoxyglucose F18, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multiple Myeloma mortality, Multiple Myeloma pathology, Prognosis, Radiopharmaceuticals, Recurrence, Stem Cell Transplantation, Multimodal Imaging methods, Multiple Myeloma diagnostic imaging, Positron-Emission Tomography, Tomography, X-Ray Computed
- Abstract
The aim of this study was to investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography-computed tomography (18F-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed. Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS (p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved to have the strongest association with disease progression. Intensity of glucose uptake and presence of extramedullary disease were associated with shorter TTP (p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). PET resulted in a change of management in 30% of patients. Our data underline the prognostic value of 18F-FDG-PET/CT in MM patients also in the setting of post-SCT relapse. PET/CT has a significant impact on patient management.
- Published
- 2014
- Full Text
- View/download PDF
5. Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology.
- Author
-
Lückerath K, Lapa C, Spahmann A, Jörg G, Samnick S, Rosenwald A, Einsele H, Knop S, and Buck AK
- Subjects
- Cell Line, Tumor, Flow Cytometry, Humans, Methionine chemical synthesis, Positron-Emission Tomography methods, Radioactive Tracers, Statistics, Nonparametric, Tyrosine chemical synthesis, Fluorodeoxyglucose F18 chemical synthesis, Methionine analogs & derivatives, Multiple Myeloma diagnosis, Multiple Myeloma metabolism, Paraproteins biosynthesis, Tyrosine analogs & derivatives
- Abstract
Purpose: Multiple myeloma is a hematologic malignancy originating from clonal plasma cells. Despite effective therapies, outcomes are highly variable suggesting marked disease heterogeneity. The role of functional imaging for therapeutic management of myeloma, such as positron emission tomography with 2-deoxy-2-[¹⁸F]fluoro-D-glucose (¹⁸F-FDG-PET), remains to be determined. Although some studies already suggested a prognostic value of ¹⁸F-FDG-PET, more specific tracers addressing hallmarks of myeloma biology, e.g. paraprotein biosynthesis, are needed. This study evaluated the amino acid tracers L-methyl-[¹¹C]-methionine (¹¹C-MET) and [¹⁸F]-fluoroethyl-L-tyrosine ((¹⁸F-Fet) for their potential to image myeloma and to characterize tumor heterogeneity., Experimental Design: To study the utility of ¹¹C-MET, ¹⁸F-Fet and ¹⁸F-FDG for myeloma imaging, time activity curves were compared in various human myeloma cell lines (INA-6, MM1.S, OPM-2) and correlated to cell-biological characteristics, such as marker gene expression and immunoglobulin levels. Likewise, patient-derived CD138⁺ plasma cells were characterized regarding uptake and biomedical features., Results: Using myeloma cell lines and patient-derived CD138⁺ plasma cells, we found that the relative uptake of ¹¹C-MET exceeds that of ¹⁸F-FDG 1.5- to 5-fold and that of ¹⁸F-Fet 7- to 20-fold. Importantly, ¹¹C-MET uptake significantly differed between cell types associated with worse prognosis (e.g. t(4;14) in OPM-2 cells) and indolent ones and correlated with intracellular immunoglobulin light chain and cell surface CD138 and CXCR4 levels. Direct comparison of radiotracer uptake in primary samples further validated the superiority of ¹¹C-MET., Conclusion: These data suggest that ¹¹C-MET might be a versatile biomarker for myeloma superior to routine functional imaging with ¹⁸F-FDG regarding diagnosis, risk stratification, prognosis and discrimination of tumor subtypes.
- Published
- 2013
- Full Text
- View/download PDF
6. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
- Author
-
Kropff M, Liebisch P, Knop S, Weisel K, Wand H, Gann CN, Berdel WE, and Einsele H
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Boronic Acids administration & dosage, Boronic Acids adverse effects, Bortezomib, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Dexamethasone administration & dosage, Dexamethasone adverse effects, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Gastrointestinal Diseases chemically induced, Hematologic Diseases chemically induced, Hematopoietic Stem Cell Transplantation, Humans, Infusions, Intravenous, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma radiotherapy, Multiple Myeloma surgery, Nervous System Diseases chemically induced, Prospective Studies, Protease Inhibitors administration & dosage, Protease Inhibitors adverse effects, Pyrazines administration & dosage, Pyrazines adverse effects, Remission Induction, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Multiple Myeloma drug therapy
- Abstract
A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1. The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2). At this dose level, 92% of patients achieved at least a partial response. The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate. No patient experienced progressive disease. The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy. The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.